How Retatrutide Is Made: Triple Agonist Development

Retatrutide (LY3437943) is the most complex incretin-based peptide ever brought to advanced clinical development. Engineering a single molecule to simultaneously activate GLP-1, GIP, and glucagon receptors required Eli Lilly's scientists to solve a molecular puzzle that many considered impossible. Here is how they did it.

The Triple Agonism Challenge

GLP-1, GIP, and glucagon receptors have distinct binding pockets and activation mechanisms. Creating one peptide that fits all three is like designing a key that opens three different locks. The solution involved using the GIP peptide as the primary backbone (similar to tirzepatide), incorporating specific amino acid substitutions that enable GLP-1 receptor binding, adding a distinct segment that engages the glucagon receptor, and attaching a fatty acid chain for albumin binding and extended half-life.

Molecular Structure

Production Complexity

Manufacturing retatrutide is more challenging than either semaglutide or tirzepatide due to the longer peptide chain with more potential for synthesis errors, tighter quality requirements to ensure consistent three-receptor affinity, more complex purification to separate the desired product from closely related impurities, and additional analytical testing to verify activity at all three receptors.

Compounding Retatrutide

Because retatrutide is not yet brand-name approved, compounding pharmacies can produce it using solid-phase peptide synthesis. Trimi works with quality-verified pharmacies that provide certificates of analysis for every batch, including peptide identity confirmation, purity greater than 95%, sterility testing, and endotoxin analysis.